$CYTK
CYTOKINETICS INC Stock $cytk

$cytk Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000156459019006580 Filed on March 07, 2019

Income Statement

Concept	2019 Q1	2018	2017 Q4
Revenue	$8.464M	$31.50M	-$18.00K
YoY Change	60.67%	135.64%	-100.05%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.440M	$31.30M	$10.26M
YoY Change	1.94%	-14.25%	53.82%
% of Gross Profit
Research & Development	$23.55M	$89.14M	$26.25M
YoY Change	6.37%	-1.29%	39.78%
% of Gross Profit
Depreciation & Amortization	$286.0K	$1.239M	$610.0K
YoY Change	-57.5%	-35.47%	177.27%
% of Gross Profit
Operating Expenses	$23.55M	$120.4M	$36.51M
YoY Change	-25.01%	-5.03%	43.46%
Operating Profit	-$24.52M	-$88.92M
YoY Change	-6.17%	-21.59%
Interest Expense	$1.170M	$3.797M	-$3.960M
YoY Change	35.57%	25.9%	647.17%
% of Operating Profit
Other Income/Expense, Net	$1.141M	$4.191M
YoY Change	35.51%	61.07%
Pretax Income	-$29.37M	-$106.3M	-$40.49M
YoY Change	-3.01%	-16.83%	-665.5%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$29.37M	-$106.3M	-$40.48M
YoY Change	-3.02%	-16.83%	-665.66%
Net Earnings / Revenue	-346.95%	-337.41%
Basic Earnings Per Share
Diluted Earnings Per Share	-$535.8K	-$1.954M	-$806.6K
COMMON SHARES
Basic Shares Outstanding	54.89M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2018	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$176.6M	$198.7M	$268.9M
YoY Change	-29.78%	-26.11%	72.09%
Cash & Equivalents	$39.41M	$42.30M	$125.2M
Short-Term Investments	$137.2M	$156.5M	$143.7M
Other Short-Term Assets	$3.100M	$2.200M	$4.300M
YoY Change	34.78%	-48.84%	95.45%
Inventory
Prepaid Expenses
Receivables	$6.600M	$6.800M	$1.112M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$186.4M	$207.7M	$274.3M
YoY Change	-31.55%	-24.28%	72.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.200M	$3.200M	$3.568M
YoY Change	0.0%	-11.11%	-1.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$16.50M
YoY Change		-100.0%	114.29%
Other Assets	$9.000M	$300.0K	$429.0K
YoY Change	2150.0%	-25.0%	114.5%
Total Long-Term Assets	$12.20M	$3.500M	$20.52M
YoY Change	60.53%	-82.93%	78.25%
TOTAL ASSETS
Total Short-Term Assets	$186.4M	$207.7M	$274.3M
Total Long-Term Assets	$12.20M	$3.500M	$20.52M
Total Assets	$198.6M	$211.2M	$294.8M
YoY Change	-29.05%	-28.36%	73.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.500M	$3.800M	$5.253M
YoY Change	4.17%	-28.3%	24.01%
Accrued Expenses	$17.40M	$15.80M	$17.39M
YoY Change	12.26%	-9.2%	-3.63%
Deferred Revenue			$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.200M	$2.600M	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$26.30M	$22.20M	$32.44M
YoY Change	-31.77%	-31.48%	-2.45%
LONG-TERM LIABILITIES
Long-Term Debt	$36.40M	$39.80M	$31.78M
YoY Change	13.91%	25.16%	16.05%
Other Long-Term Liabilities	$132.6M	$123.2M	$1.097M
YoY Change	12711.59%	2.07%	672.54%
Total Long-Term Liabilities	$169.0M	$163.0M	$32.87M
YoY Change	412.29%	6.89%	19.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.30M	$22.20M	$32.44M
Total Long-Term Liabilities	$169.0M	$163.0M	$32.87M
Total Liabilities	$195.2M	$185.2M	$185.0M
YoY Change	8.25%	0.11%	144.08%
SHAREHOLDERS EQUITY
Retained Earnings			-$646.1M
YoY Change			24.66%
Common Stock			$755.6M
YoY Change			23.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.372M	$25.90M	$109.8M
YoY Change
Total Liabilities & Shareholders Equity	$198.6M	$211.2M	$294.8M
YoY Change	-29.05%	-28.36%	73.27%

Cashflow Statement

Concept	2019 Q1	2018	2017 Q4
OPERATING ACTIVITIES
Net Income	-$29.37M	-$106.3M	-$40.48M
YoY Change	-3.02%	-16.83%	-665.66%
Depreciation, Depletion And Amortization	$286.0K	$1.239M	$610.0K
YoY Change	-57.5%	-35.47%	177.27%
Cash From Operating Activities	-$26.91M	-$101.2M	-$24.07M
YoY Change	-9.73%	-0.53%	-130.93%
INVESTING ACTIVITIES
Capital Expenditures	$257.0K	$889.0K	-$780.0K
YoY Change	-1.53%	-69.1%	-9.3%
Acquisitions
YoY Change
Other Investing Activities	$19.90M	$6.020M	$31.54M
YoY Change	-2.45%	-109.56%	-176.7%
Cash From Investing Activities	$19.64M	$5.133M	$30.76M
YoY Change	-2.44%	-107.8%	-173.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$5.117M	$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.416M	13.13M	2.190M
YoY Change	-949.23%	-94.19%	208.45%
NET CHANGE
Cash From Operating Activities	-26.91M	-101.2M	-24.07M
Cash From Investing Activities	19.64M	5.133M	30.76M
Cash From Financing Activities	4.416M	13.13M	2.190M
Net Change In Cash	-2.847M	-82.95M	8.880M
YoY Change	-70.56%	-242.2%	-75.72%
FREE CASH FLOW
Cash From Operating Activities	-$26.91M	-$101.2M	-$24.07M
Capital Expenditures	$257.0K	$889.0K	-$780.0K
Free Cash Flow	-$27.16M	-$102.1M	-$23.29M
YoY Change	-9.66%	-2.42%	-129.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-88916000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54420000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4191000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-106289000
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.95
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	157000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-106132000
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54888369
CY2018Q2	dei	Entity Public Float EntityPublicFloat	449700000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42256000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125206000
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	156475000
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	143685000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2231000
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1112000
CY2018Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	4554000
CY2017Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2158000
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4292000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	207674000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	274295000
CY2018Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	0
CY2017Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	16518000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3204000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3568000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	300000
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	429000
CY2018Q4	us-gaap	Assets Assets	211178000
CY2017Q4	us-gaap	Assets Assets	294810000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3764000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5253000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15757000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17392000
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9572000
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2607000
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	66000
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	227000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22194000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32444000
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	39806000
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	31777000
CY2018Q4	cytk	Liability Related To Sale Of Future Royalties Net LiabilityRelatedToSaleOfFutureRoyaltiesNet	122473000
CY2017Q4	cytk	Liability Related To Sale Of Future Royalties Net LiabilityRelatedToSaleOfFutureRoyaltiesNet	104650000
CY2018Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	15000000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	771000
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1097000
CY2018Q4	us-gaap	Liabilities Liabilities	185244000
CY2017Q4	us-gaap	Liabilities Liabilities	184968000
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	55000
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	54000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	768703000
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	755526000
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13368000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9761000
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	500000
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	343000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-743324000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-646081000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	25934000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	109842000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	211178000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	294810000
CY2017	cytk	Stock Issued During Period Value Royalty Purchase Agreement StockIssuedDuringPeriodValueRoyaltyPurchaseAgreement	7560000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9028000
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	206000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3173000
CY2018	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	866000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	182000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	157000
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	163000000
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	163000000
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54717906
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53960832
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54717906
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53960832
CY2017	us-gaap	Interest Expense InterestExpense	3016000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-127790000
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.59
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49404000
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	206000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-127584000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	94361000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1918000
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1167000
CY2017	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	904000
CY2017	cytk	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	12071000
CY2017	cytk	Stock Issued During Period Value Secondary Offering StockIssuedDuringPeriodValueSecondaryOffering	82370000
CY2017	cytk	Stock Issued During Period Value At Market Issuance Sales Agreement StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement	29855000
CY2018	us-gaap	Profit Loss ProfitLoss	-106289000
CY2017	us-gaap	Profit Loss ProfitLoss	-127790000
CY2018	cytk	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	17767000
CY2017	cytk	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	14028000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	9761000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	9028000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1239000
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1920000
CY2018	cytk	Interest Receivable And Amortization On Investments InterestReceivableAndAmortizationOnInvestments	-1677000
CY2017	cytk	Interest Receivable And Amortization On Investments InterestReceivableAndAmortizationOnInvestments	0
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	67000
CY2018	cytk	Non Cash Interest Expense Related To Long Term Debt NonCashInterestExpenseRelatedToLongTermDebt	920000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	225919000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-82950000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	58332000
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	112224000
CY2018	cytk	Proceeds From Sale Of Future Royalties Net Of Issuance Costs ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts	0
CY2017	cytk	Proceeds From Sale Of Future Royalties Net Of Issuance Costs ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts	90621000
CY2018	cytk	Proceeds From Issuance Of Common Stock Related To Sale Of Future Royalties Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockRelatedToSaleOfFutureRoyaltiesNetOfIssuanceCosts	0
CY2017	cytk	Proceeds From Issuance Of Common Stock Related To Sale Of Future Royalties Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockRelatedToSaleOfFutureRoyaltiesNetOfIssuanceCosts	7560000
CY2018	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	9898000
CY2017	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	1261000
CY2018	cytk	Proceeds And Payments From Stock Based Award And Warrants Net Of Issuance Costs ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts	-3234000
CY2017	cytk	Proceeds And Payments From Stock Based Award And Warrants Net Of Issuance Costs ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts	-14253000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13132000
CY2017	cytk	Non Cash Interest Expense Related To Long Term Debt NonCashInterestExpenseRelatedToLongTermDebt	635000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1119000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1088000
CY2018	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-5154000
CY2017	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1817000
CY2018	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1490000
CY2017	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1457000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2063000
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	766000
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-18750000
CY2017	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0
CY2018	cytk	Increase Decrease In Contract With Customer Liability Deferred Revenue IncreaseDecreaseInContractWithCustomerLiabilityDeferredRevenue	-6485000
CY2017	cytk	Increase Decrease In Contract With Customer Liability Deferred Revenue IncreaseDecreaseInContractWithCustomerLiabilityDeferredRevenue	1513000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-101215000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-101759000
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	240224000
CY2017	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	240413000
CY2018	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	246232000
CY2017	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	177462000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	889000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2877000
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	14000
CY2017	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5133000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-65828000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	125206000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	66874000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	42256000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	2877000
CY2017	us-gaap	Interest Paid Net InterestPaidNet	2128000
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:12pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-top:12pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, investments, long-term debt and accounts receivable.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash, cash equivalents and investments are invested in deposits with two major financial institutions in the United States. Deposits in these banks may exceed the amount of insurance provided on such deposits. </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our exposure to credit risk associated with non-payment is limited to our strategic partners Amgen Inc. (“Amgen”) and Astellas Pharma Inc. (“Astellas”) and any material non-payment from our partners would result in a material breach of the agreements underlying our strategic partnerships. </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug candidates we develop may require approvals or clearances from the U.S. Food and Drug Administration (“FDA”) or other regulatory agencies prior to commercial sales. There can be no assurance that our drug candidates will receive any of the required approvals or clearances. If we were to be denied approval, or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</p>
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26194000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23861000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22626000
CY2018	us-gaap	Depreciation Depreciation	1200000
CY2017	us-gaap	Depreciation Depreciation	1900000
CY2018Q4	cytk	Accrued Clinical And Preclinical Costs Current AccruedClinicalAndPreclinicalCostsCurrent	8618000
CY2017Q4	cytk	Accrued Clinical And Preclinical Costs Current AccruedClinicalAndPreclinicalCostsCurrent	8370000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6118000
CY2018Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	198700000
CY2017Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	285400000
CY2018	cytk	Cash Requirements Term CashRequirementsTerm	P12M
CY2018Q4	cytk	Number Of Financial Institutions NumberOfFinancialInstitutions	2
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6246000
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6534000
CY2018Q4	cytk	Cash And Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis	190654000
CY2018Q4	cytk	Cash And Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000
CY2018Q4	cytk	Cash And Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	76000
CY2018Q4	cytk	Cash And Cash Equivalents And Available For Sale Securities Debt Securities CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities	190581000
CY2018Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	700000
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0
CY2018Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	42100000
CY2017Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	31800000
CY2018Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2018Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	27065000
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6261000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1021000
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2761000
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000
CY2018Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	42000000
CY2017Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	32000000
CY2018Q4	cytk	Debt Instrument Unamortized Discount And Interest Payable DebtInstrumentUnamortizedDiscountAndInterestPayable	135000
CY2017Q4	cytk	Debt Instrument Unamortized Discount And Interest Payable DebtInstrumentUnamortizedDiscountAndInterestPayable	325000
CY2018Q4	cytk	Debt Instrument Accretion Of Final Exit Fee DebtInstrumentAccretionOfFinalExitFee	548000
CY2017Q4	cytk	Debt Instrument Accretion Of Final Exit Fee DebtInstrumentAccretionOfFinalExitFee	102000
CY2018Q4	us-gaap	Long Term Debt LongTermDebt	42413000
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	31777000
CY2018	cytk	Royalty Purchase Agreement Arrangements Consideration RoyaltyPurchaseAgreementArrangementsConsideration	100000000
CY2017	cytk	Royalty Purchase Agreement Arrangements Consideration RoyaltyPurchaseAgreementArrangementsConsideration	0
CY2018	cytk	Transaction Costs Incurred In Connection With Royalty Monetization And Rpi Common Stock TransactionCostsIncurredInConnectionWithRoyaltyMonetizationAndRpiCommonStock	1800000
CY2018	cytk	Non Cancelable Lease Expiration Month And Year NonCancelableLeaseExpirationMonthAndYear	2021-06
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3400000
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5000000
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3600000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	4700000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4800000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2500000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5957458
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1804047
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	884649
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6454037
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4461463
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.19
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.04
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.51
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.06
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.72
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.72
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M12D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	412000
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	411000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9761000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9028000
CY2018Q3	cytk	Issuance Of Warrants IssuanceOfWarrants	42253
CY2018Q3	cytk	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	7.10
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	142359
CY2018Q4	cytk	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	6.85
CY2017	cytk	Warrant Expiration Period WarrantExpirationPeriod	2017-06
CY2017	cytk	Number Of Issued Shares Of Common Stock Related To Cashless Exercise Of Warrants NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants	3450122
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.01
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.08
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.00
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.51
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.17
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.10
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.01
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.00
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.03
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-106289000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-127235000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-555000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-106289000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-127790000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	121748000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	98630000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	64797000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	64185000
CY2018Q4	cytk	Deferred Tax Assets Liability Related To Sale Of Future Royalties DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties	26294000
CY2017Q4	cytk	Deferred Tax Assets Liability Related To Sale Of Future Royalties DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties	24593000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5772000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	10524000
CY2018Q4	cytk	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	4614000
CY2017Q4	cytk	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	6432000
CY2018Q4	cytk	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	586000
CY2017Q4	cytk	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	546000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	223811000
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	204910000
CY2018Q4	cytk	Deferred Tax Liabilities Accounting Method Change DeferredTaxLiabilitiesAccountingMethodChange	2682000
CY2017Q4	cytk	Deferred Tax Liabilities Accounting Method Change DeferredTaxLiabilitiesAccountingMethodChange	0
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	20000
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2702000
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	221109000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	204910000
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2018	cytk	Research And Development Federal Tax Credit Carryforwards Expiration Date Year ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear	2021
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	16200000
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-11700000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9365000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7565000
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	110000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1800000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9475000
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8600000
CY2017Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8100000
CY2018	cytk	Tax Cuts And Jobs Act Of2017 Maximum Measurement Period Allowed For Companies To Complete Accounting TaxCutsAndJobsActOf2017MaximumMeasurementPeriodAllowedForCompaniesToCompleteAccounting	P1Y

Files In Submission

Name	View Source	Status
0001564590-19-006580-index-headers.html	Edgar Link	pending
0001564590-19-006580-index.html	Edgar Link	pending
0001564590-19-006580.txt	Edgar Link	pending
0001564590-19-006580-xbrl.zip	Edgar Link	pending
cytk-10k_20181231.htm	Edgar Link	pending
cytk-20181231.xml	Edgar Link	completed
cytk-20181231.xsd	Edgar Link	pending
cytk-20181231_cal.xml	Edgar Link	unprocessable
cytk-20181231_def.xml	Edgar Link	unprocessable
cytk-20181231_lab.xml	Edgar Link	unprocessable
cytk-20181231_pre.xml	Edgar Link	unprocessable
cytk-ex1049_468.htm	Edgar Link	pending
cytk-ex1050_393.htm	Edgar Link	pending
cytk-ex11_467.htm	Edgar Link	pending
cytk-ex231_440.htm	Edgar Link	pending
cytk-ex232_10.htm	Edgar Link	pending
cytk-ex311_11.htm	Edgar Link	pending
cytk-ex312_7.htm	Edgar Link	pending
cytk-ex313_6.htm	Edgar Link	pending
cytk-ex321_12.htm	Edgar Link	pending
cytk-ex51_466.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYTK
CYTOKINETICS INC Stock $cytk

2019 Q1 Form 10-K Financial Statement

#000156459019006580 Filed on March 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYTK CYTOKINETICS INC Stock $cytk

2019 Q1 Form 10-K Financial Statement

#000156459019006580 Filed on March 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYTK
CYTOKINETICS INC Stock $cytk